Pembrolizumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)
Pembrolizumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)
Pembrolizumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1, >95%, high purity, Human IgG4SP
Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Antibody Type
Primary antibody
Clonality
Recombinant
Isotype
Human IgG4SP
Light Chain Type
kappa
SDS-PAGE
146 kDa
Purification Method
Protein A purified
Purity
>95%
Source
CHO supernatant
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
1374853-91-4
Images
Pembrolizumab (anti-PD-1) (P411997) - Flow Cytometry Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood mononuclear lymphocytes labelling PD-1 (red) with Pembrolizumab (anti-PD-1) (P411997). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Pembrolizumab (anti-PD-1) (P411997) - SEC The purity of Pembrolizumab (anti-PD-1) (P411997) is more than 95% verified by HPLC.
Associated Targets(Human)
PDCD1TclinProgrammed cell death protein 1 (0 Activities)
1.Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer.. Discov Med, 14 (77):(229-36). [PMID:23114578][10.1021/op500134e]
2.Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy.. Blood, 121 (5):(734-44). [PMID:23223433][10.1021/op500134e]
3.Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.. Curr Oncol Rep, 15 (2):(98-104). [PMID:23263823][10.1021/op500134e]
4.Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.. N Engl J Med, 369 (2):(134-44). [PMID:23724846][10.1021/op500134e]
5.Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP et al.. (2016) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.. N Engl J Med, 374 (26):(2542-52). [PMID:27093365][10.1021/op500134e]
6.Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A et al.. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.. N Engl J Med, 379 (21):(2040-2051). [PMID:30280635][10.1021/op500134e]
7.Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B et al.. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.. N Engl J Med, 380 (12):(1116-1127). [PMID:30779529][10.1021/op500134e]
8.Saada-Bouzid E, Peyrade F, Guigay J. (2019) Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.. Curr Opin Oncol, 31 (3):(146-151). [PMID:30893146][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
ZJ24F0707872